Latest Headlines

Latest Headlines

Boehringer walks away from an anti-inflammatory deal with Orexo

Boehringer Ingelheim has handed back the rights to a drug development project targeting pain and inflammation, ending a long-standing partnership with Orexo.

Orexo gets FDA approval for opioid addiction-fighting Zubsolv

The FDA is wrestling with a host of issues surrounding highly addictive and often abused opioids and just recommended a drug that may provide some help in its effort.

Orexo stakes out $500M market for new opioid-addiction drug

Just three months after Titan Pharmaceuticals' experimental treatment for opioid addiction was red-flagged at the FDA, Orexo has cruised to an approval for a rival therapy.

Jazz CFO joins Medivation's board of directors

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Orexo, AstraZeneca join forces against respiratory disease

Sweden's Orexo has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a new therapy to treat respiratory diseases.

AstraZeneca kicks tires on respiratory program ditched by J&J

AstraZeneca CEO Pascal Soriot is banking on a deep pipeline of respiratory meds to help revive the beleaguered drug giant.

Kyowa Hakko submits Orexo's Abstral in Japan again

Orexo's Japanese partner Kyowa Hakko has resubmitted Abstral, a sublingual fentanyl tablet that delivers the opioid drug under the tongue for the treatment of breakthrough cancer pain, for marketing approval in Japan.

Sublingual opioid addiction therapy moves closer to market

Orexo, a Swedish pharma company, has submitted to the FDA a new drug application for Zubsolv (OX219), its under-the-tongue formulation of buprenorphine and naloxone for treatment of opioid dependence. The drug uses Orexo's sublingual drug delivery technology.

With J&J deal undone, Orexo revamps drug delivery tech development

Sweden's Orexo will slash jobs and focus on three development programs that rely on enhancing already-approved treatments.

Orexo inks $585M drug pact with J&J

Sweden's Orexo is pocketing $10 million from an upfront payment it will reap as part of a three-year, $585 million development pact with J&J's drug arm. The collaboration centers on preclinical